Wells Fargo analyst Tim Evans changed ratings in the Life Science Tools sector to reflect in order to prioritize the pharma end market. For a Tools company, the pharma end market is "less price sensitive, less competitive, and more receptive to product cycles," Evans tells investors in a research note. To reflect this thesis, the analyst upgraded both Mettler-Toledo (MTD) and Agilent (A) to Outperform from Market Perform. He raised his price target for Mettler to $660 from $510 and for Agilent to $67 from $60. The analyst also downgraded Bruker (BRKR) to Underperform from Market Perform with an unchanged price target of $25. His favorite name in the Life Science Tools portion of his universe is Waters (WAT).